In the first placebo-controlled study of vaporized cannabis for acute migraine, patients report greater relief from pain and ...

After 12 weeks of treatment, 75% of per-protocol patients receiving 0.05% urcosimod showed greater than 80% reduction in ...

Takeda announces positive results from two pivotal phase 3 studies of oveporexton in narcolepsy type 1: Osaka Wednesday, July 16, 2025, 16:30 Hrs [IST] Takeda, a global company fo ...

AstraZeneca has reported positive outcomes from the BaxHTN Phase III trial, indicating that the highly selective aldosterone synthase inhibitor (ASI), baxdrostat, significantly reduced the mean seated ...

Suven Life Sciences has a portfolio of advanced-stage clinical candidates and research programs designed for CNS disorders ...

Patients with knee osteoarthritis who received metformin demonstrated significant reductions in knee pain and increased ...

An FDA-funded clinical trial found even modest CBD use triggered elevated liver enzymes in some healthy adults, raising ...

Monjuvi added to Rituxan and Revlimid extended progression-free survival from 14 to 22 months in follicular lymphoma, ...

A 30-day course of antibiotics after robot-assisted radical cystectomy appears to eliminate UTIs and reduce costs of care.

Dosing of the first patient in Phase 2b marks an important transition of the RESOLVE trial from a Phase 2a open-label study ...

A motion sickness drug that treats severe depression in hours? Discover how scopolamine may revolutionize mental health ...